Novel multimeric IL-1 receptor antagonist for the treatment of rheumatoid arthritis

Biomaterials

Volumn 42, Issue , 2015, Pages 121-133

  Pasi, Shweta ^a   Kant, Ravi ^a   Gupta, Sarika ^a   Surolia, Avadhesha ^a,b  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Anakinra; IL 1 receptor antagonist; Multimeric; Rheumatoid arthritis

Indexed keywords

MAMMALS; PROTEINS;

ANAKINRA; INFLAMMATORY MEDIATORS; MULTIMERIC; PROTEIN THERAPEUTICS; RECEPTOR ANTAGONISTS; RHEUMATOID ARTHRITIS; THERAPEUTIC EFFICACY; THERAPEUTIC MOLECULES;

DISEASES;

AMYLOID BETA PROTEIN[1-42]; AMYLOID PROTEIN; HYBRID PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT 2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT 3; INTERLEUKIN 1BETA; LYSYLPHENYLALANYLPHENYLALANYL GLUTAMIC ACID; POLYMER; PROTEIN AGGREGATE; PROTEIN VARIANT; TETRAPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN MOTIF; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; ATOMIC FORCE MICROSCOPY; CELL LINE; DISEASE COURSE; PATHOLOGY; PROTEIN MULTIMERIZATION; RADIOGRAPHY;

MUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL LINE; DISEASE PROGRESSION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MICE; MICROSCOPY, ATOMIC FORCE; PROTEIN MULTIMERIZATION;

EID: 84919651150     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.11.041     Document Type: Article

References (57)

1. Seckinger P., Lowenthal J.W., Williamson K., Dayer J.M., MacDonald H.R. Aurine inhibitor of interleukin 1 activity that blocks ligand binding. JImmunol 1987, 139:1546-1549.
2. Hannum C.H., Wilcox C.J., Arend W.P., Joslin F.G., Dripps D.J., Heimdal P.L., et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990, 343:336-340.
3. Dripps D.J., Brandhuber B.J., Thompson R.C., Eisenberg S.P. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. JBiol Chem 1991, 266:10331-10336.
4. Campion G.V., Lebsack M.E., Lookabaugh J., Gordon G., Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996, 39:1092-1101.
5. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
6. Feldmann M., Brennan F.M., Maini R.N. Rheumatoid arthritis. Cell 1996, 85:307-310.
7. Kobayashi M., Squires G.R., Mousa A., Tanzer M., Zukor D.J., Antoniou J., et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005, 52:128-135.
8. Vastert S.J., de Jager W., Noordman B.J., Holzinger D., Kuis W., Prakken B.J., et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheum 2014, 66:1034-1043.
9. Swart J.F., Barug D., Mohlmann M., Wulffraat N.M. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther 2010, 10:1743-1752.
10. Kuemmerle-Deschner J.B., Tyrrell P.N., Koetter I., Wittkowski H., Bialkowski A., Tzaribachev N., et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011, 63:840-849.
11. Fitzgerald A.A., Leclercq S.A., Yan A., Homik J.E., Dinarello C.A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005, 52:1794-1803.
12. Kalliolias G.D., Georgiou P.E., Antonopoulos I.A., Andonopoulos A.P., Liossis S.N. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007, 66:842-843.
13. Nixon R., Bansback N., Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007, 46:1140-1147.
14. Mertens M., Singh J.A. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009, 1. CD005121.
15. Thaler K., Chandiramani D.V., Hansen R.A., Gartlehner G. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 2009, 3:485-498.
16. Amgen Kineret (anakinra) [summary of product information] 2001, FDA Briefing Information, 2100.
17. Maji S.K., Schubert D., Rivier C., Lee S., Rivier J.E., Riek R. Amyloid as a depot for the formulation of long-acting drugs. PLoS Biol 2008, 6. e17.
18. Gupta S., Chattopadhyay T., Pal Singh M., Surolia A. Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus. Proc Natl Acad Sci U S A 2010, 107:13246-13251.
19. Krishnan S., Raibekas A.A. Multistep aggregation pathway of human interleukin-1 receptor antagonist: kinetic, structural, and morphological characterization. Biophys J 2009, 96:199-208.
20. McIntyre K.W., Stepan G.J., Kolinsky K.D., Benjamin W.R., Plocinski J.M., Kaffka K.L., et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity invitro and modulation of acute inflammation invivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. JExp Med 1991, 173:931-939.
21. Brand D.D., Latham K.A., Rosloniec E.F. Collagen-induced arthritis. Nat Protoc 2007, 2:1269-1275.
22. Seeuws S., Jacques P., Van Praet J., Drennan M., Coudenys J., Decruy T., et al. Amultiparameter approach to monitor disease activity in collagen-induced arthritis. Arthritis Res Ther 2010, 12. R160.
23. Rochet J.C., Lansbury P.T. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 2000, 10:60-68.
24. Tjernberg L., Hosia W., Bark N., Thyberg J., Johansson J. Charge attraction and beta propensity are necessary for amyloid fibril formation from tetrapeptides. JBiol Chem 2002, 277:43243-43246.
25. Biancalana M., Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 2010, 1804:1405-1412.
26. Srinivasan R., Jones E.M., Liu K., Ghiso J., Marchant R.E., Zagorski M.G. pH-dependent amyloid and protofibril formation by the ABri peptide of familial British dementia. JMol Biol 2003, 333:1003-1023.
27. Garnero P., Landewe R., Boers M., Verhoeven A., Van Der Linden S., Christgau S., et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002, 46:2847-2856.
28. Yamanaka H., Matsuda Y., Tanaka M., Sendo W., Nakajima H., Taniguchi A., et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000, 43:852-858.
29. Andersson M.L., Svensson B., Petersson I.F., Hafstrom I., Albertsson K., Forslind K., et al. Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis. BMC Musculoskelet Disord 2013, 14:229.
30. Dinarello C.A. Interleukin-1 and interleukin-1 antagonism. Blood 1991, 77:1627-1652.
31. Kay J., Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology 2004, 43(Suppl.3):iii2-iii9.
32. van den Berg W.B. Lessons for joint destruction from animal models. Curr Opin Rheumatol 1997, 9:221-228.
33. Joosten L.A., Helsen M.M., van de Loo F.A., van den Berg W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996, 39:797-809.
34. Kim S.H., Evans C.H., Kim S., Oligino T., Ghivizzani S.C., Robbins P.D. Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res 2000, 2:293-302.
35. Drevlow B.E., Lovis R., Haag M.A., Sinacore J.M., Jacobs C., Blosche C., et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996, 39:257-265.
36. Cawthorne C., Prenant C., Smigova A., Julyan P., Maroy R., Herholz K., et al. Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [(1)(8)F]-IL1RA and PET imaging in rats. Br J Pharmacol 2011, 162:659-672.
37. Kaiser C., Knight A., Nordstrom D., Pettersson T., Fransson J., Florin-Robertsson E., et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012, 32:295-299.
38. Chang B.S., Beauvais R.M., Arakawa T., Narhi L.O., Dong A., Aparisio D.I., et al. Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution. Biophys J 1996, 71:3399-3406.
39. Alford J.R., Kendrick B.S., Carpenter J.F., Randolph T.W. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. JPharm Sci 2008, 97:3005-3021.
40. Seefeldt M.B., Kim Y.S., Tolley K.P., Seely J., Carpenter J.F., Randolph T.W. High-pressure studies of aggregation of recombinant human interleukin-1 receptor antagonist: thermodynamics, kinetics, and application to accelerated formulation studies. Protein Sci Pub Protein Society 2005, 14:2258-2266.
41. Enya M., Morishima-Kawashima M., Yoshimura M., Shinkai Y., Kusui K., Khan K., et al. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein(Abeta) dimer in the cortex during aging. Am J Pathol 1999, 154:271-279.
42. Chikanza I.C., Roux-Lombard P., Dayer J.M., Panayi G.S. Dysregulation of the invivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum 1995, 38:642-648.
43. Firestein G.S., Boyle D.L., Yu C., Paine M.M., Whisenand T.D., Zvaifler N.J., et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994, 37:644-652.
44. Arend W.P., Welgus H.G., Thompson R.C., Eisenberg S.P. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. JClin Invest 1990, 85:1694-1697.
45. Smith R.J., Chin J.E., Sam L.M., Justen J.M. Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991, 34:78-83.
46. Seckinger P., Klein-Nulend J., Alander C., Thompson R.C., Dayer J.M., Raisz L.G. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. JImmunol 1990, 145:4181-4184.
47. Bendele A., McAbee T., Sennello G., Frazier J., Chlipala E., McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999, 42:498-506.
48. Kim J.M., Jeong J.G., Ho S.H., Hahn W., Park E.J., Kim S., et al. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther 2003, 10:1543-1550.
49. van den Berg W.B. Lessons from animal models of arthritis over the past decade. Arthritis Res Ther 2009, 11:250.
50. Shamji M.F., Betre H., Kraus V.B., Chen J., Chilkoti A., Pichika R., et al. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic. Arthritis Rheum 2007, 56:3650-3661.
51. Xiao J.Q., Shi X.L., Ma H.C., Tan J.J., Lin Z., Xu Q., et al. Administration of IL-1Ra chitosan nanoparticles enhances the therapeutic efficacy of mesenchymal stem cell transplantation in acute liver failure. Arch Med Res 2013, 44:370-379.
52. Whitmire R.E., Wilson D.S., Singh A., Levenston M.E., Murthy N., Garcia A.J. Self-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins. Biomaterials 2012, 33:7665-7675.
53. Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M.E., Moreland L.W., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:614-624.
54. Jiang Y., Genant H.K., Watt I., Cobby M., Bresnihan B., Aitchison R., et al. Amulticenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000, 43:1001-1009.
55. Chung Y., Chang S.H., Martinez G.J., Yang X.O., Nurieva R., Kang H.S., et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.
56. Wilke C.M., Wang L., Wei S., Kryczek I., Huang E., Kao J., et al. Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. JTransl Med 2011, 9:217.
57. Pineda M.A., McGrath M.A., Smith P.C., Al-Riyami L., Rzepecka J., Gracie J.A., et al. The parasitic helminth product ES-62 suppresses pathogenesis in collagen-induced arthritis by targeting the interleukin-17-producing cellular network at multiple sites. Arthritis Rheum 2012, 64:3168-3178.